Search

Your search keyword '"Vanhove Bernard"' showing total 446 results
Start Over Author "Vanhove Bernard"
446 results on '"Vanhove Bernard"'

8. Concerted BAG3 and SIRPα blockade impairs pancreatic tumor growth

Author

De Marco, Margot, Gauttier, Vanessa, Pengam, Sabrina, Mary, Caroline, Ranieri, Bianca, Basile, Anna, Festa, Michela, Falco, Antonia, Reppucci, Francesca, Cammarota, Anna Lisa, Acernese, Fausto, De Laurenzi, Vincenzo, Sala, Gianluca, Brongo, Sergio, Miyasaka, Masayuki, Shalapour, Shabnam, Vanhove, Bernard, Poirier, Nicolas, Iaccarino, Roberta, Karin, Michael, Turco, Maria Caterina, Rosati, Alessandra, and Marzullo, Liberato

Published
2022
Full Text
View/download PDF

10. Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate patients with COVID-19

Author

Poulakou, Garyfallia, primary, Royer, Pierre-Joseph, additional, Evgeniev, Nikolay, additional, Evanno, Gwénaëlle, additional, Shneiker, Françoise, additional, Marcelin, Anne-Geneviève, additional, Vanhove, Bernard, additional, Duvaux, Odile, additional, Marot, Stéphane, additional, and Calvez, Vincent, additional

Published
2024
Full Text
View/download PDF

13. Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial

Author

Gaborit, Benjamin, Vanhove, Bernard, Vibet, Marie-Anne, Le Thuaut, Aurélie, Lacombe, Karine, Dubee, Vincent, Ader, Florence, Ferre, Virginie, Vicaut, Eric, Orain, Jéremie, Le Bras, Morgane, Omnes, Anne, Berly, Laetitia, Jobert, Alexandra, Morineau-Le Houssine, Pascale, Botturi, Karine, Josien, Régis, Flet, Laurent, Degauque, Nicolas, Brouard, Sophie, Duvaux, Odile, Poinas, Alexandra, and Raffi, François

Published
2021
Full Text
View/download PDF

14. Human Tolerogenic Dendritic Cells Regulate Immune Responses through Lactate Synthesis

Author

Marin, Eros, Bouchet-Delbos, Laurence, Renoult, Ophélie, Louvet, Cédric, Nerriere-Daguin, Véronique, Managh, Amy J., Even, Amandine, Giraud, Matthieu, Vu Manh, Thien Phong, Aguesse, Audrey, Bériou, Gaelle, Chiffoleau, Elise, Alliot-Licht, Brigitte, Prieur, Xavier, Croyal, Mikael, Hutchinson, James A., Obermajer, Natasa, Geissler, Edward K., Vanhove, Bernard, Blancho, Gilles, Dalod, Marc, Josien, Régis, Pecqueur, Claire, Cuturi, Maria-Cristina, and Moreau, Aurélie

Published
2019
Full Text
View/download PDF

16. XAV-19 a Glyco-Humanized polyclonal antibody targeting SARS-CoV-2 accelerates the recovery of mild to moderate COVID-19 patients and keeps its neutralizing activity against Omicron and its subvariants

Author

Poulakou, Garyfallia, primary, Royer, Pierre-Joseph, additional, Evgeniev, Nikolai, additional, Evanno, Gwénaëlle, additional, Shneiker, Françoise, additional, Vanhove, Bernard, additional, Duvaux, Odile, additional, Marot, Stéphane, additional, and Calvez, Vincent, additional

Published
2023
Full Text
View/download PDF

18. IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease

Author

Belarif, Lyssia, Danger, Richard, Kermarrec, Laetitia, Nerriere-Daguin, Veronique, Pengam, Sabrina, Durand, Tony, Mary, Caroline, Kerdreux, Elise, Gauttier, Vanessa, Kucik, Aneta, Thepenier, Virginie, Martin, Jerome C., Chang, Christie, Rahman, Adeeb, Guen, Nina Salabert-Le, Braudeau, Cecile, Abidi, Ahmed, David, Gregoire, Malard, Florent, Takoudju, Celine, Martinet, Bernard, Gerard, Nathalie, Neveu, Isabelle, Neunlist, Michel, Coron, Emmanuel, MacDonald, Thomas T., Desreumaux, Pierre, Mai, Hoa-Le, Bas-Bernardet, Stephanie Le, Mosnier, Jean-Franqois, Merad, Miriam, Josien, Regis, Brouard, Sophie, Soulillou, Jean-Paul, Blancho, Gilles, Bourreille, Arnaud, Naveilhan, Philippe, Vanhove, Bernard, and Poirier, Nicolas

Subjects
Crohn's disease -- Research -- Genetic aspects, Interleukins -- Research, Ulcerative colitis -- Research -- Genetic aspects, Inflammatory bowel diseases -- Research, T cells -- Research, Tumor necrosis factor, Anti-inflammatory agents, Inflammation, B cells, Colitis, Medical research, Integrins, Health care industry
Abstract

It remains unknown what causes inflammatory bowel disease (IBD), including signaling networks perpetuating chronic gastrointestinal inflammation in Crohn's disease (CD) and ulcerative colitis (UC), in humans. According to an analysis of up to 500 patients with IBD and 100 controls, we report that key transcripts of the IL-7 receptor (IL-7R) pathway are accumulated in inflamed colon tissues of severe CD and UC patients not responding to either immunosuppressive/corticosteroid, anti- TNF, or anti-[[alpha].sub.4][[beta].sub.7] therapies. High expression of both IL7R and IL-7R signaling signature in the colon before treatment is strongly associated with nonresponsiveness to anti-TNF therapy. While in mice IL-7 is known to play a role in systemic inflammation, we found that in humans IL-7 also controlled [[alpha].sub.4][[beta].sub.7] integrin expression and imprinted gut-homing specificity on T cells. IL-7R blockade reduced human T cell homing to the gut and colonic inflammation in vivo in humanized mouse models, and altered effector T cells in colon explants from UC patients grown ex vivo. Our findings show that failure of current treatments for CD and UC is strongly associated with an overexpressed IL-7R signaling pathway and point to IL-7R as a relevant therapeutic target and potential biomarker to fill an unmet need in clinical IBD detection and treatment., Introduction Inflammatory bowel disease (IBD) consists of 2 major forms, ulcerative colitis (UC) and Crohn's disease (CD), which are chronic relapsing gastrointestinal disorders characterized by chronic intestinal inflammation, dysregulated immune [...]

Published
2019
Full Text
View/download PDF

19. Long-Term IgG Response to Porcine Neu5Gc Antigens without Transmission of PERV in Burn Patients Treated with Porcine Skin Xenografts

Author

Scobie, Linda, Padler-Karavani, Vered, Le Bas-Bernardet, Stephanie, Crossan, Claire, Blaha, Josef, Matouskova, Magda, Hector, Ralph D, Cozzi, Emanuele, Vanhove, Bernard, Charreau, Beatrice, Blancho, Gilles, Bourdais, Ludovic, Tallacchini, Mariachiara, Ribes, Juan M, Yu, Hai, Chen, Xi, Kracikova, Jitka, Broz, Ludomir, Hejnar, Jiri, Vesely, Pavel, Takeuchi, Yasuhiro, Varki, Ajit, and Soulillou, Jean-Paul

Subjects
Biotechnology, Prevention, Clinical Research, Autoimmune Disease, Adolescent, Adult, Aged, Animals, Antigens, Heterophile, Burns, Child, Endogenous Retroviruses, Enzyme-Linked Immunosorbent Assay, Female, Humans, Immunoglobulin G, Infant, Male, Middle Aged, RNA, Viral, Reverse Transcriptase Polymerase Chain Reaction, Sialic Acids, Skin Transplantation, Swine, Transplantation, Heterologous, Immunology
Abstract

Acellular materials of xenogenic origin are used worldwide as xenografts, and phase I trials of viable pig pancreatic islets are currently being performed. However, limited information is available on transmission of porcine endogenous retrovirus (PERV) after xenotransplantation and on the long-term immune response of recipients to xenoantigens. We analyzed the blood of burn patients who had received living pig-skin dressings for up to 8 wk for the presence of PERV as well as for the level and nature of their long term (maximum, 34 y) immune response against pig Ags. Although no evidence of PERV genomic material or anti-PERV Ab response was found, we observed a moderate increase in anti-αGal Abs and a high and sustained anti-non-αGal IgG response in those patients. Abs against the nonhuman sialic acid Neu5Gc constituted the anti-non-αGal response with the recognition pattern on a sialoglycan array differing from that of burn patients treated without pig skin. These data suggest that anti-Neu5Gc Abs represent a barrier for long-term acceptance of porcine xenografts. Because anti-Neu5Gc Abs can promote chronic inflammation, the long-term safety of living and acellular pig tissue implants in recipients warrants further evaluation.

Published
2013

23. CD28 blockade controls T cell activation to prevent graft-versus-host disease in primates

Author

Watkins, Benjamin K., Tkachev, Victor, Furlan, Scott N., Hunt, Daniel J., Betz, Kayla, Yu, Alison, Brown, Melanie, Poirier, Nicolas, Zheng, Hengqi Betty, Taraseviciute, Agne, Colonna, Lucrezia, Mary, Caroline, Blancho, Gilles, Soulillou, Jean-Paul, Panoskaltsis- Mortari, Angela, Sharma, Prachi, Garcia, Anapatricia, Strobert, Elizabeth, Hamby, Kelly, Garret, Aneesah, Deane, Taylor, Blazar, Bruce R., Vanhove, Bernard, and Kean, Leslie S.

Subjects
Graft vs. host disease -- Care and treatment -- Models, Immune response -- Health aspects, Membrane proteins -- Physiological aspects -- Health aspects, T cells -- Physiological aspects -- Health aspects, Health care industry
Abstract

Controlling graft-versus-host disease (GVHD) remains a major unmet need in stem cell transplantation, and new, targeted therapies are being actively developed. CD28-CD80/86 costimulation blockade represents a promising strategy, but targeting CD80/CD86 with CTLA4-Ig may be associated with undesired blockade of coinhibitory pathways. In contrast, targeted blockade of CD28 exclusively inhibits T cell costimulation and may more potently prevent GVHD. Here, we investigated FR104, an antagonistic CD28-specific pegylated-Fab', in the nonhuman primate (NHP) GVHD model and completed a multiparameter interrogation comparing it with CTLA4-Ig, with and without sirolimus, including clinical, histopathologic, flow cytometric, and transcriptomic analyses. We document that FR104 monoprophylaxis and combined prophylaxis with FR104/sirolimus led to enhanced control of effector T cell proliferation and activation compared with the use of CTLA4-Ig or CTLA4- Ig/sirolimus. Importantly, FR104/sirolimus did not lead to a beneficial impact on Treg reconstitution or homeostasis, consistent with control of conventional T cell activation and IL-2 production needed to support Tregs. While FR104/sirolimus had a salutary effect on GVHD-free survival, overall survival was not improved, due to death in the absence of GVHD in several FR104/ sirolimus recipients in the setting of sepsis and a paralyzed INF-[gamma] response. These results therefore suggest that effectively deploying CD28 in the clinic will require close scrutiny of both the benefits and risks of extensively abrogating conventional T cell activation after transplant., Introduction Graft-versus-host disease (GVHD) represents a major cause of mortality after hematopoietic stem cell transplant (HCT) (1-4), and despite substantial effort, the control of GVHD remains one of the key [...]

Published
2018
Full Text
View/download PDF

25. Corrigendum: XAV-19, a swine glyco-humanized polyclonal antibody against SARS-CoV-2 spike receptor-binding domain, targets multiple epitopes and broadly neutralizes variants

Author

Vanhove, Bernard, primary, Marot, Stéphane, additional, So, Ray T., additional, Gaborit, Benjamin, additional, Evanno, Gwénaëlle, additional, Malet, Isabelle, additional, Lafrogne, Guillaume, additional, Mevel, Edwige, additional, Ciron, Carine, additional, Royer, Pierre-Joseph, additional, Lheriteau, Elsa, additional, Raffi, François, additional, Bruzzone, Roberto, additional, Mok, Chris Ka Pun, additional, Duvaux, Odile, additional, Marcelin, Anne-Geneviève, additional, and Calvez, Vincent, additional

Published
2023
Full Text
View/download PDF

27. Effect of Swine Glyco-humanized Polyclonal Neutralizing Antibody on Survival and Respiratory Failure in Patients Hospitalized With Severe COVID-19: A Randomized, Placebo-Controlled Trial.

Author

Gaborit, Benjamin, Vanhove, Bernard, Lacombe, Karine, Guimard, Thomas, Hocqueloux, Laurent, Perrier, Ludivine, Dubee, Vincent, Ferre, Virginie, Bressollette, Celine, Josien, Régis, Thuaut, Aurélie Le, Vibet, Marie-Anne, Jobert, Alexandra, Dailly, Eric, Ader, Florence, Brouard, Sophie, Duvaux, Odile, Raffi, François, and group, for the POLYCOR study

Subjects
*SARS-CoV-2, *RESPIRATORY insufficiency, *COVID-19, *AUJESZKY'S disease virus
Abstract

Background We evaluated the safety and efficacy of XAV-19, an antispike glyco-humanized swine polyclonal neutralizing antibody in patients hospitalized with severe coronavirus disease 2019 (COVID-19). Methods This phase 2b clinical trial enrolled adult patients from 34 hospitals in France. Eligible patients had a confirmed diagnosis of severe acute respiratory syndrome coronavirus 2 within 14 days of onset of symptoms that required hospitalization for low-flow oxygen therapy (<6 L/min of oxygen). Patients were randomly assigned to receive a single intravenous infusion of 2 mg/kg of XAV-19 or placebo. The primary end point was the occurrence of death or severe respiratory failure between baseline and day 15. Results Between January 12, 2021, and April 16, 2021, 398 patients were enrolled in the study and randomly assigned to XAV-19 or placebo. The modified intention-to-treat population comprised 388 participants who received full perfusion of XAV-19 (199 patients) or placebo (189 patients). The mean (SD) age was 59.8 (12.4) years, 249 (64.2%) individuals were men, and the median time (interquartile range) from symptom onset to enrollment was 9 (7–10) days. There was no statistically significant decrease in the cumulative incidence of death or severe respiratory failure through day 15 in the XAV-19 group vs the placebo group (53/199 [26.6%] vs 48/189 [25.4%]; adjusted risk difference, 0.6%; 95% CI, −6% to 7%; hazard ratio, 1.03; 95% CI, 0.64–1.66; P =.90). In the safety population, adverse events were reported in 75.4% of 199 patients in the XAV-19 group and in 76.3% of 190 patients in the placebo group through D29. Conclusions Among patients hospitalized with COVID-19 requiring low-flow oxygen therapy, treatment with a single intravenous dose of XAV-19, compared with placebo, did not show a significant difference in terms of disease progression at day 15. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

28. LIS1, a glyco-humanized swine polyclonal anti-lymphocyte globulin, as a novel induction treatment in solid organ transplantation

Author

Rousse, Juliette, primary, Royer, Pierre-Joseph, additional, Evanno, Gwénaëlle, additional, Lheriteau, Elsa, additional, Ciron, Carine, additional, Salama, Apolline, additional, Shneiker, Françoise, additional, Duchi, Roberto, additional, Perota, Andrea, additional, Galli, Cesare, additional, Cozzi, Emmanuele, additional, Blancho, Gilles, additional, Duvaux, Odile, additional, Brouard, Sophie, additional, Soulillou, Jean-Paul, additional, Bach, Jean-Marie, additional, and Vanhove, Bernard, additional

Published
2023
Full Text
View/download PDF

29. LIS1, a glyco-humanized swine polyclonal anti-lymphocyte globulin, as a novel induction treatment in solid organ transplantation

Author

Rousse, Juliette, primary, Royer, Pierre-Joseph, additional, Evanno, Gwenaëlle, additional, Lheriteau, Elsa, additional, Ciron, Carine, additional, Salama, Apolline, additional, Shneiker, Françoise, additional, Duchi, Roberto, additional, Perota, Andrea, additional, Galli, Cesare, additional, Cozzi, Emmanuele, additional, Blancho, Gilles, additional, Duvaux, Odile, additional, Brouard, Sophie, additional, Soulillou, Jean-Paul, additional, Bach, Jean-Marie, additional, and Vanhove, Bernard, additional

Published
2022
Full Text
View/download PDF

30. IL-7 receptor blockade blunts antigen-specific memory T cell responses and chronic inflammation in primates

Author

Belarif, Lyssia, Mary, Caroline, Jacquemont, Lola, Mai, Hoa Le, Danger, Richard, Hervouet, Jeremy, Minault, David, Thepenier, Virginie, Nerrière-Daguin, Veronique, Nguyen, Elisabeth, Pengam, Sabrina, Largy, Eric, Delobel, Arnaud, Martinet, Bernard, Le Bas-Bernardet, Stéphanie, Brouard, Sophie, Soulillou, Jean-Paul, Degauque, Nicolas, Blancho, Gilles, Vanhove, Bernard, and Poirier, Nicolas

Published
2018
Full Text
View/download PDF

34. Anti-SARS-CoV-2 swine glyco-humanized polyclonal antibody XAV-19 retains neutralizing activity against SARS-CoV-2 B.1.1.529 (Omicron)

Author

Vanhove, Bernard, primary, Marot, Stephane Sylvain, additional, Evanno, Gwenaelle, additional, Mallet, Isabelle, additional, Rouvray, Gaetane, additional, Shneiker, Francoise, additional, Mevel, Edwige, additional, Ciron, Carine, additional, Rousse, Juliette, additional, Royer, Pierre-Joseph, additional, Lheriteau, Elsa, additional, Raffi, Francois, additional, Duvaux, Odile, additional, Marcelin, Anne-Genevieve, additional, and Calvez, Vincent, additional

Published
2022
Full Text
View/download PDF

35. Xenotransplantation: The Current Status of Understanding

Author

Bach, Fritz H., Van der Werf, Willem J., Blakely, Martin L., Vanhove, Bernard, de Martin, Rainer, Winkler, Hans, Touraine, J. L., editor, Traeger, J., editor, Bétuel, H., editor, Dubernard, J. M., editor, Revillard, J. P., editor, and Dupuy, C., editor

Published
1994
Full Text
View/download PDF

36. Il-7 receptor blockade following T cell depletion promotes long-term allograft survival

Author

Mai, Hoa-Le, Boeffard, Francoise, Longis, Julie, Danger, Richard, Martinet, Bernard, Haspot, Fabienne, Vanhove, Bernard, Brouard, Sophie, and Soulillou, Jean-Paul

Subjects
Homografts -- Research, Interleukin-7 -- Physiological aspects -- Research, Graft rejection -- Research, Immunosuppression -- Research, Health care industry
Abstract

T cell depletion is commonly used in organ transplantation for immunosuppression; however, a restoration of T cell homeostasis following depletion leads to increased memory T cells, which may promote transplant rejection. The cytokine IL-7 is important for controlling lymphopoiesis under both normal and lymphopenic conditions. Here, we investigated whether blocking IL-7 signaling with a mAb that targets IL-7 receptor α (IL-7Rα) alone or following T cell depletion confers an advantage for allograft survival in murine transplant models. We found that IL-7R blockade alone induced indefinite pancreatic islet allograft survival if anti-IL-7R treatment was started 3 weeks before graft. IL-7R blockade following anti-CD4- and anti-CD8-mediated T cell depletion markedly prolonged skin allograft survival. Furthermore, IL-7 inhibition in combination with T cell depletion synergized with either CTLA-4Ig administration or suboptimal doses of tacrolimus to induce long-term skin graft acceptance in this stringent transplant model. Together, these therapies inhibited T cell reconstitution, decreased memory T cell numbers, increased the relative frequency of Tregs, and abrogated both cellular and humoral alloimmune responses. Our data suggest that IL-7R blockade following T cell depletion has potential as a robust, immunosuppressive therapy in transplantation., Introduction T cell depletion by antibodies is one of the most potent immunosuppressive therapies and is increasingly used as an induction therapy in organ transplantation (1). However, T cell homeostasis [...]

Published
2014
Full Text
View/download PDF

39. XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants

Author

Vanhove, Bernard, primary, Marot, Stéphane, additional, So, Ray T., additional, Gaborit, Benjamin, additional, Evanno, Gwénaëlle, additional, Malet, Isabelle, additional, Lafrogne, Guillaume, additional, Mevel, Edwige, additional, Ciron, Carine, additional, Royer, Pierre-Joseph, additional, Lheriteau, Elsa, additional, Raffi, François, additional, Bruzzone, Roberto, additional, Mok, Chris Ka Pun, additional, Duvaux, Odile, additional, Marcelin, Anne-Geneviève, additional, and Calvez, Vincent, additional

Published
2021
Full Text
View/download PDF

41. Inhibition of acid sphingomyelinase increases regulatory T cells in humans

Author

Wiese, Teresa, Dennstädt, Fabio, Hollmann, Claudia, Stonawski, Saskia, Wurst, Catherina, Fink, Julian, Gorte, Erika, Mandasari, Putri, Domschke, Katharina, Hommers, Leif, Vanhove, Bernard, Schumacher, Fabian, Kleuser, Burkard, Seibel, Jürgen, Rohr, Jan, Buttmann, Mathias, Menke, Andreas, Schneider-Schaulies, Jürgen, and Beyersdorf, Niklas

Subjects
sphingolipids, AcademicSubjects/SCI01870, antidepressants, hemic and immune systems, chemical and pharmacologic phenomena, Original Article, AcademicSubjects/MED00310, ddc:610, acid sphingomyelinase, major depression, regulatory T cells
Abstract

Genetic deficiency for acid sphingomyelinase or its pharmacological inhibition has been shown to increase Foxp3+ regulatory T-cell frequencies among CD4+ T cells in mice. We now investigated whether pharmacological targeting of the acid sphingomyelinase, which catalyzes the cleavage of sphingomyelin to ceramide and phosphorylcholine, also allows to manipulate relative CD4+ Foxp3+ regulatory T-cell frequencies in humans. Pharmacological acid sphingomyelinase inhibition with antidepressants like sertraline, but not those without an inhibitory effect on acid sphingomyelinase activity like citalopram, increased the frequency of Foxp3+ regulatory T cell among human CD4+ T cells in vitro. In an observational prospective clinical study with patients suffering from major depression, we observed that acid sphingomyelinase-inhibiting antidepressants induced a stronger relative increase in the frequency of CD4+ Foxp3+ regulatory T cells in peripheral blood than acid sphingomyelinase-non- or weakly inhibiting antidepressants. This was particularly true for CD45RA− CD25high effector CD4+ Foxp3+ regulatory T cells. Mechanistically, our data indicate that the positive effect of acid sphingomyelinase inhibition on CD4+ Foxp3+ regulatory T cells required CD28 co-stimulation, suggesting that enhanced CD28 co-stimulation was the driver of the observed increase in the frequency of Foxp3+ regulatory T cells among human CD4+ T cells. In summary, the widely induced pharmacological inhibition of acid sphingomyelinase activity in patients leads to an increase in Foxp3+ regulatory T-cell frequencies among CD4+ T cells in humans both in vivo and in vitro., In their study, Wiese et al. found that pharmacological inhibition of acid sphingomyelinase with antidepressants such as sertraline or amitriptyline increased the proportion of Foxp3+ regulatory T cells among human CD4+ T cells both in cell culture in vitro as well as in vivo in patients treated for major depression., Graphical Abstract Graphical Abstract

Published
2021

42. Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study

Author

Gaborit, Benjamin, primary, Dailly, Eric, additional, Vanhove, Bernard, additional, Josien, Régis, additional, Lacombe, Karine, additional, Dubee, Vincent, additional, Ferre, Virginie, additional, Brouard, Sophie, additional, Ader, Florence, additional, Vibet, Marie-Anne, additional, Le Thuaut, Aurélie, additional, Danger, Richard, additional, Flet, Laurent, additional, Omnes, Anne, additional, Berly, Laetitia, additional, Chiffoleau, Anne, additional, Jobert, Alexandra, additional, Duvaux, Odile, additional, and Raffi, François, additional

Published
2021
Full Text
View/download PDF

43. hCTLA4-Ig transgene expression in keratocytes modulates rejection of corneal xenografts in a pig to non-human primate anterior lamellar keratoplasty model

Author

Vabres, Bertrand, Le Bas-Bernardet, Stéphanie, Riochet, David, Chérel, Yan, Minault, David, Hervouet, Jérémy, Ducournau, Yvette, Moreau, Anne, Daguin, Véronique, Coulon, Flora, Pallier, Annaïck, Brouard, Sophie, Robson, Simon C., Nottle, Mark B., Cowan, Peter J., Venturi, Eric, Mermillod, Pascal, Brachet, Philippe, Galli, Cesare, Lagutina, Irina, Duchi, Roberto, Bach, Jean-Marie, Blancho, Gilles, Soulillou, Jean-Paul, and Vanhove, Bernard

Published
2014
Full Text
View/download PDF

46. Cystathionine‐gamma‐lyase overexpression in T cells enhances antitumor effect independently of cysteine autonomy

Author

Lancien, Melanie, primary, Gueno, Lucile, additional, Salle, Sonia, additional, Merieau, Emmanuel, additional, Beriou, Gaelle, additional, Nguyen, Tuan H., additional, Abidi, Ahmed, additional, Dilek, Nahzli, additional, Solomon, Pierre, additional, Poschmann, Jeremie, additional, Michielin, Olivier, additional, Vuillefroy de Silly, Romain, additional, Vanhove, Bernard, additional, and Louvet, Cedric, additional

Published
2021
Full Text
View/download PDF

47. High neutralizing potency of swine glyco‐humanized polyclonal antibodies against SARS‐CoV‐2

Author

Vanhove, Bernard, primary, Duvaux, Odile, additional, Rousse, Juliette, additional, Royer, Pierre‐Joseph, additional, Evanno, Gwénaëlle, additional, Ciron, Carine, additional, Lheriteau, Elsa, additional, Vacher, Laurent, additional, Gervois, Nadine, additional, Oger, Romain, additional, Jacques, Yannick, additional, Conchon, Sophie, additional, Salama, Apolline, additional, Duchi, Roberto, additional, Lagutina, Irina, additional, Perota, Andrea, additional, Delahaut, Philippe, additional, Ledure, Matthieu, additional, Paulus, Melody, additional, So, Ray T., additional, Mok, Chris Ka‐Pun, additional, Bruzzone, Roberto, additional, Bouillet, Marc, additional, Brouard, Sophie, additional, Cozzi, Emanuele, additional, Galli, Cesare, additional, Blanchard, Dominique, additional, Bach, Jean‐Marie, additional, and Soulillou, Jean‐Paul, additional

Published
2021
Full Text
View/download PDF

48. Transgenic expression of CTLA4-Ig by fetal pig neurons for xenotransplantation

Author

Martin, Caroline, Plat, Martine, Nerrière-Daguin, Véronique, Coulon, Flora, Uzbekova, Svetlana, Venturi, Eric, Condé, Françoise, Hermel, Jean-Michel, Hantraye, Philippe, Tesson, Laurent, Anegon, Ignacio, Melchior, Benoit, Peschanski, Marc, Mauff, Brigitte Le, Boeffard, Françoise, Sergent-Tanguy, Solène, Neveu, Isabelle, Naveilhan, Philippe, Soulillou, Jean-Paul, Terqui, Michel, Brachet, Philippe, and Vanhove, Bernard

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results